uniQure (NASDAQ:QURE) Price Target Cut to $14.00 by Analysts at Royal Bank of Canada

uniQure (NASDAQ:QURE) had its price target trimmed by Royal Bank of Canada from $16.00 to $14.00 in a research note published on Wednesday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. StockNews.com upgraded shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of uniQure in a report on Tuesday, August 20th. The Goldman Sachs Group upped their price target on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research report on Wednesday. Finally, Raymond James reissued an “outperform” rating and issued a $20.00 target price on shares of uniQure in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Trading Up 18.2 %

uniQure stock opened at $7.16 on Wednesday. uniQure has a 52-week low of $3.73 and a 52-week high of $11.35. The company has a market cap of $348.69 million, a P/E ratio of -1.21 and a beta of 0.90. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06. The business has a 50-day simple moving average of $5.70 and a two-hundred day simple moving average of $5.79.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently modified their holdings of QURE. Mirae Asset Global Investments Co. Ltd. grew its stake in uniQure by 74.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 157,312 shares of the biotechnology company’s stock valued at $818,000 after acquiring an additional 66,958 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after purchasing an additional 30,054 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after buying an additional 109,740 shares in the last quarter. Acadian Asset Management LLC boosted its stake in uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the last quarter. Finally, Covestor Ltd grew its holdings in uniQure by 103.2% during the 1st quarter. Covestor Ltd now owns 53,690 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 27,267 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.